Edwards Lifesciences Corp
Change company Symbol lookup
Select an option...
EW Edwards Lifesciences Corp
COP ConocoPhillips
FBP First Bancorp
PTCT PTC Therapeutics Inc
ROKU Roku Inc
WORK Slack Technologies Inc
ARKW ARK Next Generation Internet ETF
SPOT Spotify Technology SA
GBTC Grayscale Bitcoin Trust (BTC)
ARKK ARK Innovation ETF

Health Care : Health Care Equipment & Supplies | Large Cap Growth
Company profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Closing Price
Day's Change
0.38 (0.43%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

UPDATE: Airline stocks see broad gains after the busiest travel weekend in 8 months

11:35 am ET November 23, 2020 (MarketWatch)

Tomi Kilgore

More than 3 million people went through TSA checkpoints over the weekend, including a record 1.05 million on Sunday

Shares of air carriers were broadly higher Monday, following the busiest travel weekend in eight months and more good news on a potential COVID-19 vaccine.

The U.S. Global Jets exchange-traded fund (JETS) rallied 1.5% in morning trading toward the highest close in five months, while the Dow Jones Transportation Average climbed 0.7% with all six of its air-carrier components gaining ground.

Among the most active in the sector, shares of American Airlines Group Inc. (AAL) rose 4.1%, United Airlines Holding Inc. (UAL) advanced 2.7% and Delta Air Lines Inc. (DAL) hiked up 3.0%.

Data provided from the Transportation Security Administration (TSA) showed that 3,052,139 people went through TSA checkpoints over the three days (https://www.tsa.gov/coronavirus/passenger-throughput) through Sunday, despite calls from top health officials refrain from traveling (https://www.marketwatch.com/story/many-americans-still-flying-for-thanksgiving-despite-cdc-pleas-01606083022) for Thanksgiving as COVID-19 cases surge. That's the most people to travel over a weekend since 4.7 million people traveled over the three days ending Sunday, March 15.

Also read: U.S. coronavirus case tally tops 12 million amid growing fears that Thanksgiving travel will spark another surge of infections (https://www.marketwatch.com/story/us-coronavirus-case-tally-tops-12-million-amid-growing-fears-that-thanksgiving-travel-will-spark-another-surge-of-infections-2020-11-23).

Over 1 million people traveled on both Friday and Sunday, with Sunday's total of 1,047,934 the highest one-day total since 1,257,823 people traveled on March 16.

Not only are more people traveling, they appear to be paying more to do so.

Analyst Helane Becker at Cowen said her research indicates that fares of the domestic routes she tracks for American, Delta and United for the week ended Nov. 16 were up 5.2% from the same period a year ago.

Elsewhere, shares of JetBlue Airways Corp. (JBLU) gained 0.9%, Alaska Air Group Inc. (ALK) rose 1.6%, Southwest Airlines Co. (LUV) edged up 0.1%, Spirit Airlines Inc. (SAVE) tacked on 1.9% and Hawaiian Airlines parent Hawaiian Holdings Inc. (HA) rallied 1.7%.

Also helping bolster airline investor enthusiasm, U.K.-based drugmaker AstraZeneca PLC (AZN.LN) said Monday that the COVID-19 vaccine candidate it was developing with the University of Oxford showed in Phase 3 trials that it can be as much as 90% effective (https://www.marketwatch.com/story/astrazeneca-oxford-covid-19-vaccine-can-be-up-to-90-effective-late-stage-trials-show-11606121833).

That is the third vaccine candidate to show high levels of efficacy, following those of Pfizer Inc. (PFE) and BioNTech SE (BNTX) last week and of Moderna Inc. (MRNA) the week before.

The Jets ETF has rallied 26.7% over the past three months, but has still shed 33.1% year to date. In comparison, the S&P 500 index has gained 4.8% the past three months and advanced 10.2% this year.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

November 23, 2020 11:35 ET (16:35 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.